Amgen (AMGN) Debt to Equity (2009 - 2026)

Amgen's Debt to Equity history runs 18 years deep, the most recent figure standing at $6.24 for Q1 2026.

• In Q1 2026, Debt to Equity fell 32.53% year-over-year to $6.24; the TTM figure through Mar 2026 stood at $6.24 (down 32.53% YoY), while the FY2025 annual figure was $6.31, down 38.33% from the prior year.
• Debt to Equity was $6.24 for Q1 2026 at Amgen, down from $6.31 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $40.23 in Q1 2022 to a low of $5.67 in Q3 2025.
• Historically, Debt to Equity has averaged $11.3 across 5 years, with a median of $10.23 in 2024.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity jumped 1048.97% in 2022, then tumbled 71.37% in 2023.
• A 5-year view of Debt to Equity shows it stood at $10.64 in 2022, then fell by 2.54% to $10.37 in 2023, then dropped by 1.37% to $10.23 in 2024, then sank by 38.33% to $6.31 in 2025, then declined by 1.1% to $6.24 in 2026.
• The last three Debt to Equity figures came in at $6.24 (Q1 2026), $6.31 (Q4 2025), and $5.67 (Q3 2025), per Business Quant data.